CClinicalTrials.gg
CompletedNCT02507427Updated Feb 15, 2019

Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study)

A Phase 1/2 interventional study of NIM-Eclipse in Prostate Cancer, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Seoul National University Hospital · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
19 Years to 80 Years
Sex
Male
01

Study summary

To evaluate the safety and efficacy of pelvic autonomic nerve monitoring and mapping during robot assisted laparoscopic radical prostatectomy for preservation of erectile function.

Read the detailed description

Using NIM-Eclipse monitoring instrument (Medtronic), we will check action potential of cavernous nerve, bulbocavernosus reflex and pudendal nerve somatosensory evoked potential in real time during robot assisted laparoscopic radical prostatectomy for preservation of erectile function. In this feasibility and protocol setting phase I/II study, we will evaluate the safety and efficacy of pelvic autonomic nerve monitoring and mapping using NIM-Eclipse monitoring instrument.

02

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer, robot, nerve mapping and monitoring
03

In context

Prostatic Neoplasms

6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.

This study's enrollment of 30 is below the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • pathologically proven localized prostate cancer (≤cT3a)
  • patients to undergo robot-assisted laparoscopic prostatectomy at our center

Exclusion criteria

Exclusion Criteria:

  • prior hormone therapy
  • prior radiation treatment on prostate or pelvis
  • refused to participate
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Nerve monitoring arm

    They will receive pelvic autonomic nerve monitoring and mapping using NIM-Eclipse (Medtronic) during robot-assisted laparoscopic prostatectomy.

    Device: NIM-Eclipse

Interventions

  • DeviceNIM-Eclipse

    Using NIM-Eclipse, nerve monitoring and mapping are performed

06

What researchers measure

Primary outcomes

  1. Completion rate of nerve monitoring and mapping during RALP

    Completion rate of planed surgery without significant intra-operative complication

    Time frame: During the operation

Secondary outcomes

  1. Adverse event

    Rate of adverse events during and after procedures upto 12 months

    Time frame: 12 months

  2. Quantification of erectile nerve preservation

    Changes in action potential after prostate removal from the baseline. Electrical stimulation will be given at each neurovascular bundle 3 times. Action potential will be measured at both corpus cavernosum.

    Time frame: During the operation

  3. Correlation between the quantification and subjective nerve preservation grade

    Mean value of the quantification by nerve preservation grade (Tewari et al, 2011) which was subjectively scored by the surgeon.

    Time frame: During the operation

  4. Correlation between the quantification of erectile nerve preservation and the postoperative recovery of erectile function

    Recovery duration of erection measured by the International Index of Erectile Dysfunction(IIEF)-5 score according to the quantification of erectile nerve preservation

    Time frame: 12 months

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No — No part of IPD will be shared.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02507427
Lead sponsor
Seoul National University Hospital
Responsible party
Chang Wook Jeong (Seoul National University Hospital, Seoul National University Hospital) — Principal investigator
First posted
Jul 24, 2015
Start date
Jul 26, 2015
Primary completion
Mar 19, 2017
Completion
Mar 19, 2018
Last update
Feb 15, 2019

Study contacts

Chang Wook Jeong, M.D., Ph.D
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion